By Jamie Martin
Syngenta, a global leader in agricultural innovation, has announced significant expansions in its biologicals sector by acquiring key assets from Novartis and inaugurating a new production facility in South Carolina, USA. This strategic move is set to transform the landscape of sustainable agriculture.
“We invest significantly to offer the industry’s most advanced pipeline of innovative agricultural solutions,” said Camilla Corsi, Global Head of Crop Protection Research and Development at Syngenta.
The acquisition includes Novartis's repository of natural compounds and genetic strains specifically for agricultural use, enhancing Syngenta’s research capabilities in biologicals.
In addition to the acquisition, Syngenta has launched its first world-scale production facility for agricultural biologicals in the U.S. Located in Orangeburg, South Carolina, this facility will cater to the growing demand for biological solutions in North and Latin America.
Syngenta’s commitment to biologicals has been evident since its acquisition of Italy’s Valagro in 2020. Biologicals, which include biocontrols, biostimulants, and nutrient use efficiency products, are essential for promoting regenerative agriculture and supporting more sustainable farming practices.
Jonathan Brown, Global Head of Syngenta’s Seedcare and Biologicals business, emphasized, “With the broadest and most comprehensive portfolio across all segments of biological products, we have established ourselves as a leader in the industry.” This expansion is part of Syngenta's broader strategy to innovate continuously in a growing market.
Through these initiatives, Syngenta is not only enhancing its product offerings but also significantly contributing to the sustainability of global agriculture, aligning with its commitment to environmental stewardship and agricultural productivity.
Photo Credit: syngenta
Categories: National